Alembic Pharma gets USFDA nod for cancer treatment drug
The company has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Erlotinib tablets in the strengths of 25 mg, 100 mg, and 150 mg, Alembic Pharmaceuticals said in a regulatory filing.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | New Drug Applications | Pharmaceuticals | Tarceva